NSAIDs: safety from the point of evidence-based medicine

Cover Page

Cite item

Full Text

Abstract

Prescribing of NSAIDs in modern clinical practice is a routine procedure. However, all aspects of NSAIDs safety are often not assessed. The article highlights the main aspects of safe prescription of NSAIDs, which every doctor should be guided in his practice.

About the authors

G. S Anikin

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: medi321@mail.ru
119992, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

I. V Stozhkova

Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation

клин. ординатор 1-го года 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

V. G Kukes

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

акад. РАН, д-р мед. наук, проф. 119992, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

References

  1. Starling A.J, Hoffman-Snyder C. Risk of development of medication overuse headache with nonsteroidal anti-inflammatory drug therapy for migraine: a critically appraised topic. Neurologist 2011; 17 (5): 297-9.
  2. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res 2015; 8: 105-18.
  3. Smyth E.M, Grosser T, Wang M. et al. Prostanoids in health and disease. J Lipid Res 2009; 50: S423-8.
  4. Grosser T, Fries S, FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15.
  5. Funk C.D, FitzGerald G.A. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007; 50: 470-9.
  6. Schmidt M, Lamberts M, Olsen A.M. et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group of cardiovascular pharmacotherapy of the European Society of Cardiology. Eur Heart J 2016; 37: 1015-23.
  7. Ye Y, Martinez J.D, Perez-Polo R.J et al. The role of eNOS, iNOS, and NFkB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 2008; 295: 343-51.
  8. Liuni A, Luca M.C, Gori T, Parker J.D. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism. J Am Coll Cardiol 2010; 55: 1002-6.
  9. Johnson A.G, Nguyen T.V, Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289-300.
  10. Chan C.C, Reid C.M, Aw T.J. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis et al. J Hypertens 2009; 27: 2332-41.
  11. Trelle S, Reichenbach S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: с7086.
  12. McGettigan P, Henry D. Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med 2011; 8 (9): e1001098.
  13. https://www.fda.gov/Drugs/DrugSafety/ucm451800.htm
  14. Nagata N, Niikura R. et al. Lower GI bleeding risk of nonsteroidal anti-inflammatory drugs and antiplatelet drug use alone and the effect of combined therapy. Gastrointest Endosc 2014, Aug 1.
  15. Евсеев М.А. НПВП-индуцированные гастродуоденальные язвы, осложненные кровотечением. Рус. мед. журн. 2006; 14 (15): 3-10
  16. Singh et al. Gastrointestinal Tract Complications of Nonsteroidal Anti-inflammatory Drug Treatment in Rheumatoid Arthritis. Arch Intern Med 1996; 156: 1530-6.
  17. Massó González EL et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010; 62 (6): 1592-601.
  18. Malfertheiner P et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66 (1): 6-30.
  19. Lanza F.L. et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104 (3): 728-38.
  20. Rubenstein J.H, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20 (4): 373-80.
  21. Sanchez-Matienzo D. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther 2006; 28 (8): 1123-32.
  22. García Rodríguez L.A, Williams R, Derby L.E. et al. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994; 154 (3): 311-6.
  23. Harris R.C. Cyclooxygenase-2 and the kidney: functional and pathophysiological. J Hypertens 2002; 20: S3-S9.
  24. Fagagnini S, Heinrich H. et al. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS One 2017; 12 (10): e0185193.
  25. Ingrasciotta Y, Sultana J, Giorgianni F. et al. Association of Individual Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case Control Study. PLoS ONE 2015; 10 (4): e0122899.
  26. Ungprasert P, Cheungpasitporn W, Crowson C.S. Matteson Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. EL Eur J Intern Med 2015; 26 (4): 285.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).